The board of directors of Shanghai Henlius Biotech, Inc. announced that, recently, clinical trial application for the recombinant anti-CTLA-4 fully human monoclonal antibody injection (" HLX13 ") developed by the Company (for the treatment of unresectable or metastatic melanoma, advanced renal cell carcinoma and microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer and also for adjuvant treatment of melanoma), has been accepted by the National Medical Products Administration (the "NMPA"). Ipilimumab (trade name: Yervoy®) is a fully human, anti-CTLA-4 (cytotoxic T-lymphocytes-associated antigen 4, also known as CD152), IgG1 monoclonal antibody with light chain. HLX13 is a biosimilar of Ipilimumab independently developed by the Company. It is primarily applicable to the treatment of the following indications: 1. unresectable or metastatic melanoma; 2. adjuvant treatment of melanoma; 3. advanced renal cell carcinoma; and 4. microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer. CTLA-4 mainly expresses in regulatory T cells (Treg) and activated T cells and is designed to inhibit the growth of T cells and the creation of the cytokine (IL-2 and IFN-) by competing with CD28 for the B7 ligands (B7-1 and B7-2) attached to antigen-presenting cells. By blocking the binding between CTLA-4 and the ligands, Ipilimumab can elevate the immune response and in turn achieve the goal of killing tumours.